These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 27748796)
1. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing. He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796 [TBL] [Abstract][Full Text] [Related]
2. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls. Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568 [TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing. Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497 [TBL] [Abstract][Full Text] [Related]
4. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354 [TBL] [Abstract][Full Text] [Related]
5. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers. Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547 [TBL] [Abstract][Full Text] [Related]
6. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301 [TBL] [Abstract][Full Text] [Related]
7. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250 [TBL] [Abstract][Full Text] [Related]
8. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases. Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084 [TBL] [Abstract][Full Text] [Related]
9. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027 [TBL] [Abstract][Full Text] [Related]
10. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria. Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808 [TBL] [Abstract][Full Text] [Related]
11. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912 [TBL] [Abstract][Full Text] [Related]
12. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644 [TBL] [Abstract][Full Text] [Related]
13. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370 [TBL] [Abstract][Full Text] [Related]
14. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing. Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823 [TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901 [TBL] [Abstract][Full Text] [Related]
16. Revolutionizing Non-Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma. Lee JY; Jeon S; Jun HR; Sung CO; Jang SJ; Choi CM; Chun SM Cancer Res Treat; 2024 Apr; 56(2):484-501. PubMed ID: 37871897 [TBL] [Abstract][Full Text] [Related]
17. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352 [TBL] [Abstract][Full Text] [Related]
18. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer. Ohira T; Sakai K; Matsubayashi J; Kajiwara N; Kakihana M; Hagiwara M; Hibi M; Yoshida K; Maeda J; Ohtani K; Nagao T; Nishio K; Ikeda N Cancer Sci; 2016 Nov; 107(11):1660-1666. PubMed ID: 27575703 [TBL] [Abstract][Full Text] [Related]
19. Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer. Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S Anticancer Res; 2018 Oct; 38(10):5627-5634. PubMed ID: 30275180 [TBL] [Abstract][Full Text] [Related]
20. Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma. DiBardino DM; Saqi A; Elvin JA; Greenbowe J; Suh JH; Miller VA; Ali SM; Stoopler M; Bulman WA Clin Lung Cancer; 2016 Nov; 17(6):517-522.e3. PubMed ID: 27378171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]